



Amarin Corporation plc
 Investor Relations Department
 2 Pembroke House, Upper
 Pembroke
 Street 28-32
 Dublin 2
 Ireland

[Visit IR website](#)
[Sign-up for Email alerts](#)

| NASDAQ: AMRN | |
|---------------|----------------------------|
| Last Trade: | 4.10 |
| Trade Time: | 4:00 PM ET Jul 26, 2017 |
| Change: | 0.04 (+0.985%) |
| Day Range | 4.03 - 4.15 |
| 52-Week Range | 2.19 - 4.47 |
| Volume | 1,812,252 |

Stock information is provided by eSignal,
 stock charts provided by EDGAR Online.
 Stock data is delayed approximately 20
 minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 26, 2017
[Amarin to Report Second Quarter 2017 Results and Host Conference Call on August 2, 2017](#)
- Jun 12, 2017
[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides](#)
- Jun 1, 2017
[Amarin to Present at the Jefferies 2017 Global Healthcare Conference](#)
- May 18, 2017
[Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care](#)
- May 3, 2017
[Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations](#)

Upcoming Events [\[View all \]](#)

- Aug 2, 2017 8:00 AM ET
[Amarin Q2 Results Conference Call](#)
- Financials [\[View all \]](#)**
- [First Quarter Financial Results](#)
- Mar 1, 2017
[Annual Report \(10-K\)](#)
- Apr 21, 2017
[Proxy Statement \(DEF 14A\)](#)
- May 3, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016
[Quarterly Report \(10-Q\)](#)